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Abstract 
Hyperglycemia-induced oxidative stress is implicated in the development of 
cardiomyopathy in diabetes that is associated with reduced adiponectin (APN) and 
heme oxygenase-1(HO-1). Brahma-related gene 1 (Brg1) assists nuclear 
factor-erythroid-2-related factor-2 (Nrf2) to activate HO-1 to increase myocardial 
antioxidant capacity in response to oxidative stress. We hypothesized that reduced 
adiponectin (APN) impairs HO-1 induction which contributes to the development of 
diabetic cardiomyopathy, and that supplementation of APN may ameliorate diabetic 
cardiomyopathy by activating HO-1 through Nrf2 and Brg1 in diabetes. Control (C) 
and streptozotocin-induced diabetic (D) rats were untreated or treated with APN 
adenovirus (1*109 pfu) three weeks after diabetes induction and examined and 
terminated one week afterward. Rat left ventricular functions were assessed by 
pressure-volume conductance system, before the rat hearts being removed to perform 
histological and biochemical assays. Four weeks after diabetes induction, D rats 
developed cardiac hypertrophy evidenced as increased ratio of heart weight to body 
weight, elevated myocardial collagen I content, and larger cardiomyocyte 
cross-sectional area (all P<0.05 vs. C). Diabetes elevated cardiac oxidative stress 
(increased 15-F2t-isoprostane, 4-hydroxynonenal generation, 
8-Hydroxy-2’-deoxyguanosine, and superoxide anion generation), increased 
myocardial apoptosis, and impaired cardiac function (all P<0.05 vs. C). In D rats, 
myocardial HO-1 mRNA and protein expression were reduced which was associated 
with reduced Brg1 and nuclear Nrf2 protein expression. All these changes were either 
attenuated or prevented by APN. In primarily cultured cardiomyocytes (CMs) isolated 
from D rats or in the embryonic rat cardiomyocytes cell line H9C2 cells incubated 
with high glucose (HG, 25mM), supplementation of recombined globular APN (gAd, 
2μg/mL) reversed HG-induced reductions of HO-1, Brg1, and nuclear Nrf2 protein 
expression and attenuated cellular oxidative stress, myocyte size, and apoptotic cells. 
Inhibition of HO-1 by ZnPP (10μM) or small interfering RNA (siRNA) cancelled all 
the above gAd beneficial effects. Moreover, inhibition of Nrf2 (either by the Nrf2 
inhibitor, luteolin or siRNA) or Brg1 (by siRNA) cancelled gAd-induced HO-1 
induction and cellular protection in CMs and in H9C2 cells incubated with HG. In 
summary, our present study demonstrated that APN reduced cardiac oxidative stress, 
ameliorated cardiomyocyte hypertrophy, and prevented left ventricular dysfunction in 
diabetes by concomitantly activating Nrf2 and Brg1 to facilitate HO-1 induction. 
 
Keywords: Nuclear factor-erythroid-2-related factor-2, Adiponectin, Brahma-related 
gene 1, Cardiac hypertrophy, Diabetes 
Introduction 
Cardiovascular complications and myocardial hypertrophy are the leading causes of 
death in patients with diabetes mellitus. Clinically, this complication is characterized 
initially as myocardial hypertrophy and apoptosis, which then progresses to left 
ventricular diastolic dysfunction and eventually cardiac failure[1]. 
Hyperglycemia-induced oxidative stress has been considered as the main cause that 
triggers hypertrophic responses and apoptosis in the diabetic heart[2]. Therefore, 
therapies that can reduce oxidative stress may effectively attenuate the development 
and progression of diabetic cardiomyopathy.  
 
Heme oxygenase-1 (HO-1), a stress-inducible enzyme with anti-apoptotic and 
anti-inflammatory properties, has been demonstrated as an important mediator in 
cytoprotective defense mechanism against oxidative insults and cardiac hypertrophy 
through the antioxidant capacity of its metabolite biliverdin and bilirubin, as well as 
the anti-inflammatory actions of its metabolite carbon monoxide[3]. Induction of 
HO-1 plays a key role in anesthetic propofol-mediated attenuation of 
hyperglycemia-induced cardiac hypertrophy[4]. Overexpression of HO-1 not only 
protects cardiomyocytes from angiotensin II-induced cardiac hypertrophy via 
suppressing reactive oxygen species (ROS) overproduction in vivo and in vitro[3] but 
also attenuates myocardial apoptosis and improves pathological left ventricular 
remodeling in the failing heart[5]. Thus, interventions that can enhance HO-1 
induction may serve as a promising therapy against hyperglycemia-induced cardiac 
hypertrophy. However, the mechanism governing HO-1 induction in the heart of 
diabetic subjects and its importance in combating diabetic cardiomyopathy remain 
unclear.  
 
Recent studies have demonstrated the importance of nuclear factor-erythroid-2-related 
factor-2 (Nrf2) as an upstream stimulator of HO-1[6, 7]. Deficiency of Nrf2 impairs 
HO-1 induction and exaggerates oxidative stress both in angiotensin-II induced 
myocardial hypertrophy[8] and in hearts under pressure overload[9]. While 
enhancement of Nrf2 attenuates the development of diabetic cardiomyopathy through 
increasing HO-1 in type 1 diabetic mouse[10]. Of note, Nrf2-mediated HO-1 
induction needs the participation of brahma-related gene 1 (Brg1), a key subunit of 
ATP-dependent remodeling complexes. In response to oxidative stress, Nrf2 recruits 
Brg1 for Z-DNA formation and RNA polymerase II recruitment, which is critical in 
Nrf2-mediated inducible expression of HO-1[11, 12]. Although over-expression of 
Brg1 has been shown to mediate inflammation-induced endothelial injury in the 
pathogenesis of atherosclerosis[13], our previous finding showed that STZ-induced 
diabetic rats exhibited cardiomyopathy and dysfunction  that was associated with 
reduced myocardial Brg1. Antioxidant treatment with N-acetylcysteine (NAC)[14] 
not only restored cardiac Brg1 expression but also attenuated diabetic cardiac 
hypertrophy and dysfunction[1]. More importantly, NAC significantly attenuated the 
reductions in cardiac and systemic levels of adiponectin (APN), an adipocyte-derived 
protein with anti-diabetic and anti-inflammatory properties that has been shown to 
ameliorate pressure-induced[15] and angiotensin II-stimulated[16] cardiac 
hypertrophy. NAC mediated attenuation of diabetic cardiomyopathy is also associated 
with restoration of cardiac HO-1 expression[17]. However, the relative importance 
and especially the potential interplay among APN, Nrf2 and Brg1 in the context of 
hyperglycemia induced oxidative stress and diabetic cardiomyopathy has not been 
elucidated. 
 
APN deficiency has been shown to exacerbate concentric cardiac hypertrophy and 
increase mortality in response to pressure overload[15]. However, plasma and cardiac 
APN levels are reduced in diabetic patients[18] and STZ-induced diabetic rats[19, 20]. 
Moreover, oxidative stress can down-regulate APN level and impair APN 
cardioprotective signaling pathways[20, 21]. All these suggest that reduction of APN 
may be the major factor that rendered the diabetic hearts more sensitive to 
hyperglycemia-induced hypertrophy and cardiac dysfunction. Given that APN and 
HO-1 pathways are interactive and HO-1 induction mediated cardioprotection in the 
diabetic rats involves the enhancement of APN production[22], it is plausible that 
APN supplementation may attenuate cardiac hypertrophy and cardiac dysfunction via 
increasing HO-1 induction in diabetes which needs the participation of Nrf2 and 
Brg1. 
 
We, therefore, hypothesized that APN may inhibit hyperglycemia-induced 
cardiomyocyte hypertrophy and apoptosis and improve cardiac function in vivo by a 
mechanism involving the activation of Nrf2 and the subsequent HO-1 induction, and 
this process needs the participation of Brg1.
Research Design and Methods 
Animals and Induction of Diabetes 
Male Sprague-Dawley rats (250 ± 8g, 6-8 weeks) obtained from the Laboratory 
Animal Unit (The University of Hong Kong) were used in this study. All rats were 
housed in a room at controlled temperature (23 ± 1ºC) with a 12 hours light-dark 
cycle, and given free access to standard chow and water. Type 1 diabetes was induced 
as described[23]. Briefly, STZ was injected via tail vein at a dose of 65 mg/kg body 
weight (Sigma-Aldrich, St. Louis, MO) in 0.1 M citrate buffer (pH 4.5) or citrate 
buffer alone as control under anesthesia. One week after STZ injection, rats exhibiting 
hyperglycemia (blood glucose 16.7 mmol/L) were considered diabetic and subjected 
to outlined experiments. At termination (4 weeks after diabetes induction), cardiac 
functions were determined, rats were then deeply anesthetized with sodium 
pentobarbital (65 mg/kg), and hearts were either rapidly excised for cardiomyocyte 
isolation or frozen in lipid nitrogen for later analysis. All experimental protocols used 
in this study were approved by the Committee on the Use of Live Animals in 
Teaching and Research of The University of Hong Kong (reference number: 
2684-12). 
Animal Experimental Protocol 
Rats were randomly divided into four groups (n=8 per group): control (C), diabetes 
(D), diabetes treated with adiponectin adenovirus (D + APN, 1 * 109 pfu) or luciferase 
as control (D + LacZ, 1 * 109 pfu). Recombinant adenovirus expressing adiponectin 
or luciferase was tail-vein-injected into rats 1 week prior to tissue collection[20]. The 
increased expression level of adiponectin was confirmed by enzyme-linked 
immunosorbent assay kit (AdipoGen, Inc., Incheon, South Korea). The lowest level of 
adiponectin that can be detected by this assay is 50 pg/mL as described in the assay 
kit’s instruction with the most reliable detection range between 1.5-12 ng/ml, and as 
such our samples were diluted accordingly before performing the assay, and the 
intra-assay and inter-assay variances (%CV) range were 9.4% and 10.5%, 
respectively.  
Measurement of Left Ventricular Function 
The global cardiac functions were monitored by using a pressure-volume (PV) 
conductance catheter (AD Instruments, Colorado Springs, CO, USA) placed into the 
left ventricle through right carotid artery and connected to a computer equiped with an 
advantage PV control box software (AD Instruments, Colorado Springs, CO, USA) as 
previously described[23]. The cardiac functional parameters were recorded, including 
heart rate (HR); left ventricular end-systolic pressure (Pes); left ventricular 
end-diastolic pressure (Ped); stroke volume (SV); left ventricular ejection fraction 
(EF); stroke work (SW); cardiac output (CO). The load-independent contractility 
parameters including the maximal slope of systolic pressure increment (dP/dt max); 
arterial elastance (Ea = LVESP/SV); diastolic decrement (dP/dt min); the relaxation 
time constant calculated by Weiss method (Tau) were analyzed using Labchart 8 
software (AD Instruments, Colorado Springs, CO, USA). 
Measurement of Cardiomyocytes Cross-sectional Area 
After the completion of 4 weeks’ treatment, cardiomyocytes cross-sectional diameters 
were assessed by hematoxylin-eosin-stained paraffin-embedded sections of left 
ventricles (5μm) longitudinally orientated to the muscle fibers in the sub-endocardium 
and subepicardium as previously described[1]. Cross-sectional areas were randomly 
selected in five fields that visualized capillary profiles and nuclei. Images of the left 
ventricle sections were captured by an Axisoplus image-capturing system (Zeiss) and 
analyzed by Axiovision Rel. 4.5 image analyzing software. A minimum of 150 cells 
per animal was chosen for analysis. 
Apoptotic Cell Death Detection Using Terminal Deoxynucleotidyl Transferase 
dUTP Nick-End Labeling 
Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) reaction 
was performed using an in situ cell death detection kit (Roche Diagnostics GmbH, 
Mannheim, Germany) as previously described[4]. The sections were observed in the 
light microscope by an investigator who was initially blinded to treatment groups, and 
five randomly selected fields of each slide were analyzed, and the apoptotic index was 
calculated as a percentage of apoptotic nuclei to total nuclei. 
Immunohistochemical Assay for Collagen I, 4-hydroxynonenal (4-HNE), and 
8-Hydroxy-2’-deoxyguanosine (8-OHdG) 
Paraffin-embedded left ventricular tissue blocks were sectioned at 5 µm. Then, the 
sections were dewaxed and rehydrated. Slides were incubated in 3% hydrogen 
peroxide/methanol. Antigen retrieval was performed by heating in 10 mM sodium 
citrate buffer for 10 min. Sections were incubated in anti-collagen I antibody (abcam, 
USA), or anti-4-HNE antibody (abcam, USA), or 8-OHdG (Santa Cruz, USA) at 
1:500 dilution for 12 hrs at 4 ºC. 3,3′-Diaminobenzidine Substrate Chromogen System 
(Dako, S1699) was employed in the detection procedure. Subsequently, the sections 
were counterstained with hematoxylin for 30s. Finally, the sections were dehydrated 
in ethanol, cleared in xylene, mounted, and observed in the light microscope. The 
sections were observed in light microscope by an investigator who was initially 
blinded to treatment groups, and five randomly selected fields of each slide were 
semi-quantified and averaged using the software Image J 1.48 (National Institutes of 
Health) according to its instructions. 
Detection of Left Ventricle Tissue Reactive Oxygen Species (ROS) Production by 
In Situ DHE (Dihydroethidium) Staining 
Levels of in situ O2
·- production were detected by DHE (Sigma-Aldrich) staining as 
described[24]. DHE binds to DNA upon oxidization by O2
·- to generate fluorescent 
ethidium bromide, and the resulting fluorescence intensity reflects the quantity of 
ROS production. Frozen sections of left ventricular tissue (20 μm) were incubated 
with 7.5 µM DHE at 37 ºC for 30min. Fluorescence images of ethidium bromide were 
obtained with a fluorescence microscope (BX41System microscope; Olympus) and 
the images were captured by a DP72 digital camera. The fluorescence of 
DHE-labelled positive nuclei was calculated in each of five randomly selected fields 
and are expressed as a percentage of the DHE-stained positive myocyte nuclei 
compared with control by a quantitative morphometric method[25]. 
Determination of Cardiac 15-F2t-Isoprostane and 8-OHdG 
Free 15-F2t-Isoprostane (15-F2t-IsoP), a specific marker of oxidative stress, was 
measured using an enzyme-linked immunoassay kit as we described[20]. 
Homogenized heart tissues were purified using Affinity Sorbent and Affinity Column 
(Cayman Chemical, Ann Arbor, MI) and then processed for analysis. The values of 
free 15-F2t-IsoP were expressed as pg/g protein in cardiac homogenates. The lowest 
level of 15-F2t-IsoP that can be detected by this assay kit is 2.7 pg/mL as described in 
the assay kit’s instruction with the most reliable detection range between 
12.5-80pg/ml, and as such our samples were diluted accordingly before performing 
the assay, and the intra-assay and inter-assay variances (%CV) of this assay were 
11.5% and 9.8%, respectively in our study. 8-OHdG, a specific marker of oxidative 
damage of DNA by ROS, was determined by a commercially available 8-OHdG EIA 
kit (Cayman chemical, Ann Arbor, MI) according to the manufacturer’s 
instructions[26]. The lowest level of 8-OHdG that can be detected by this assay is 33 
pg/mL, and most reliable detection range is between 117 pg/ml and 590 pg/ml 
according to that described by the assay kit manufacturer. The heart tissue samples 
were homogenized and processed for assay after proper dilution, and the intra-assay 
and inter-assay variances (%CV) were 6.8% and 8.6%, respectively in our study. 
Adult Rat Ventricular Cardiomyocytes Isolation and Treatment 
Calcium-tolerant cardiomyocytes were prepared from rat ventricles via a modified 
method as previously described[27]. Cells isolated from a single rat heart were plated 
on Matrigel-coated culture dishes and allowed to recover for 3 hrs. Cultured 
ventricular cardiomyocytes were incubated in normal glucose (NG, 5.5 mM) or high 
glucose (HG, 25 mM) or HG in the presence of Nrf2 inhibitor luteolin (Lut, 20 μM) or 
HO inhibitor zinc protoporphyrin (ZnPP, 10 μM) at 37 ̊C in Medium 199 (Gibco, 
Grand Island, NY) for 48 hours, some of the subgroup were treated with recombinant 
globular adiponectin (gAd, 2 µg/mL) for 24 hours before sample collection. Each 
experiment was performed at least times independently in triplicate. 
Nrf2 siRNA, Brg1 siRNA, and HO-1 siRNA Studies in H9C2 Cells 
Embryonic rat cardiac H9C2 cells were maintained in Dulbecco’s modified Eagle’s 
medium containing 10% FBS in a humidified atmosphere (5% CO2) at 37 ̊C. 
Commercial Nrf2 small interfering RNA (siRNA), Brg1 siRNA, and HO-1 siRNA 
(Santa Cruz Biotechnology) were used for the inhibition of Nrf2, Brg1 and HO-1 
expression per the manufacturer’s protocol as previously described[4]. After 
transfection with control siRNA, Nrf2 siRNA, Brg1 siRNA, or HO-1 siRNA, cells 
were incubated in either NG or HG in Dulbecco’s modified Eagle’s medium for 36 
hours, some of the subgroup were treated with gAd (2 µg/mL) for 24 hours and 
snap-frozen in liquid nitrogen. Each experiment was performed at least times 
independently in triplicate. 
Measurement of Cardiomyocyte Surface Area 
H9C2 cells were stained with phalloidin-tetramethylrhodamine conjugate (Santa Cruz 
Biotechnology) as previously described[4]. The cell surface area was determined with 
image analysis software Image J 1.48 (National Institutes of Health) and calculated as 
the mean of 100 cells of 5 randomly selected fields. 
Measurement of Cellular ROS in Cultured Cardiomyocytes 
Superoxide generation in cultured cardiomyocytes was estimated by DHE staining as 
previously described[24]. Briefly, cardiomyocytes were loaded with DHE at a 
concentration of 10 μM for 30 min at 37 ºC. The DHE fluorescence of DHE-labelled 
positive nuclei were calculated in each of five randomly selected fields and were 
expressed as a percentage of the DHE-stained positive myocyte nuclei compared with 
control by a quantitative morphometric method[24]. 
Determination of Cellular Injury 
Cell apoptosis was detected by double immunofluorescence staining of TUNEL using 
the In Situ Cell Death Detection Kit (Roche, Indianapolis, USA) as described[4]. 
Mitochondrial membrane potential (MMP) loss was measured using a JC-1 
mitochondrial membrane potential assay kit (Cayman chemical) as described[17]. 
Cell lactate dehydrogenase (LDH) content was measured with a LDH Cytotoxicity 
Assay Kit (Roche, Indianapolis, USA) as described[27]. 
Isolation of Cytosolic and Nuclear Fractions 
Hearts from control and STZ treated rats were cleared of blood by washing 
thoroughly in Tyrode buffer and aortic and atrial sections removed from the ventricles. 
Ventricular tissue was freeze-clamped in liquid nitrogen, and stored until fractionated 
to isolate cytosolic and nuclear fractions according to the manufacturer’s protocol as 
described in the Nuclear and Cytoplasmic Extraction Kit (Thermo, Chicago, IL). 
Extraction of Total RNA and Quantitative Real-Time Polymerase Chain 
Reaction Analysis 
Total RNA was extracted from using Trizol (Invitrogen Life Technologies, Carlsbad, 
CA), and quantitative real-time polymerase chain reaction (PCR) was performed with 
a SYBR green PCR master mix (Applied Biosystems, Foster City, CA) on a 7300 
ABI-Prizm Sequence Detector (Applied Biosystems) as described[4]. Gene-specific 
primers were as follows: rat HO-1 forward: 5’-TGCTCGCATGAACACTCTG-3’, 
reverse: 5’-TCCTCTGTCAGCAGTGCCT-3’; 18s RNA, served as an endogenous 
control, forward: 5’-CGGCTACCACATCCAAGGAA-3’, reverse: 5’-GCTGGAATT 
ACCGCGGCT-3’. 
Western Blot Analysis 
Equal protein amounts from isolated cardiomyocytes, H9C2 cells, and rat heart 
homogenate were resolved by 7.5-12.5% SDS-PAGE and subsequently transferred to 
polyvinylidene nitrocellulose membranes and processed as previously described[27]. 
The primary antibodies against collagen I, caspase-3, β-actin, and histone H3 were 
purchased from Cell Signaling Technology (Beverly, MA), Nrf2 and Brg1 antibodies 
was purchased from Abcam (Cambridge, MA), HO-1 antibody was purchased from 
Santa cruz (Santa Cruz Biotechnology, Dallas, TX). Immunoreactive bands were 
visualized by enzymatic chemiluminescence method and quantified with Quantity 
One image software. 
Statistical Analysis 
All the values were expressed as mean ± standard error of the mean (S.E.M). 
One-way analysis of variance (ANOVA) was used for statistical analyses (GraphPad 
Prism, USA) of data obtained within the same group of rats and between groups of 
rats, respectively, followed by Tukey’s test for multiple comparisons of group means. 
P<0.05 was considered statistically significant. 
Results 
General Characteristics of Control and Diabetic Rats Treated With or Without 
Adiponectin 
As shown in Table 1, 4 weeks STZ-induced diabetic rats display hyperglycemia, 
polydipsia, and polyphagia evidenced as increased plasma glucose, water intake, and 
food consumption (P<0.05 vs. C). Blood glucose was significantly increased 
associated reduced plasma and heart tissue APN in D group then that in C group 
(P<0.05). Body weight were lower while the heart/body weight ratio was higher in D 
group than that in the C group (P<0.05), APN supplementation significantly reduced 
heart/body weight ratio but has no impact on body weight despite that it significantly 
reduced food consumption and water intake. APN treatment significantly reduced 
plasma glucose level and restored plasma and heart tissue APN content (P<0.05 vs. 
D).  
 
Adiponectin Attenuated Cardiac Dysfunction in Diabetic Rats 
As shown in Table 2, cardiac function in rats after 4 weeks of diabetes was impaired, 
evidenced as reductions in basal HR, SV, SW, CO, and prolonged relaxation time 
constant (Tau, an index of diastolic function) while Ea was increased (all P<0.05 vs. 
control). The Pes, EF, dP/dtmax, and dP/dtmin were also significantly decreased in 
diabetic rats, while the Ped was not altered. The diabetes-induced reductions in SV, 
SW, EF, and Pes were reversed by adiponectin. Also, adiponectin partially recovered 
CO, dP/dtmax, and dP/dtmin in diabetic rats although the respective values were still 
lower than those in C rats (P<0.05). Adiponectin significantly attenuated the increases 
of Ea and Tau in diabetic rats.  
 
Adiponectin Reduced Myocardial Oxidative Stress, Cardiomyocyte Hypertrophy, 
and Apoptosis in Diabetic Rats 
Myocardial levels of 4-HNE (Fig. 1A and B)- a marker of lipid peroxidation, cardiac 
levels of 15-F2t-Isoprotane (Fig. 1C)-a specific index of ROS-induced oxidative stress,  
cardiac levels of 8-OHdG-a marker of oxidative damage to DNA (Fig. 1D-F), and 
myocardial superoxide anion generation (number of DHE-labelled nuclei, Fig.1G and 
H) were significantly increased in D rats compared to C rats, and this was 
accompanied with increased myocyte cross-sectional area (Fig. 1I and J) (an 
indication of cardiomyocyte hypertrophy) and abundance in myocardial collagen I 
content (Fig. 1K) (an indication of cardiac fibrosis) and cardiac collagen I protein 
expression (Fig. 1L) in D rats compared to C. Cardiomyocyte apoptosis was 
significantly increased in D rats, evidenced as increased cleaved caspase-3 protein 
expression (Fig. 1N) and increased number of TUNEL-staining positive cells (Fig. 
1M and O). APN supplementation prevented these changes in diabetes (Fig. 1A-O). 
 
Adiponectin Increased Cardiac Expression of Brg1, HO-1 and Nuclear Nrf2 in 
Diabetic Rats 
Diabetes significantly increased cytosolic Nrf2 protein retention (Fig. 2A) resulting in 
reduced nuclear Nrf2 protein expression in the myocardium (Fig. 2B), wherever APN 
supplementation significantly reduced cytosolic Nrf2 protein expression and increased 
nuclear Nrf2 protein expression, indicating an increased Nrf2 nuclear translocation 
and activation after APN treatment (Fig. 2A and B). Myocardial HO-1 mRNA and 
protein expression were significantly decreased in D compared to C (Fig. 2C and D), 
this was associated with reduced cardiac Brg1 protein expression in D rats (Fig. 2E). 
APN treatment significantly attenuated the reductions of mRNA and protein 
expression of HO-1 and attenuated the reduction of Brg1 protein expression in D rats 
(Fig. 2C-E). 
 
Globular Adiponectin Attenuated HG-induced Cardiomyocyte Oxidative Stress 
and Apoptosis by Enhancing Nrf2, Brg1, and HO-1 Protein Expression 
In cultured isolated cardiomyocytes, the number of DHE-labelled positive nuclei was 
significantly increased in cardiomyocytes exposed to HG than that exposed to NG, 
and globular adiponectin (gAd) treatment attenuated this change. However the 
protective effects of gAd were abolished by either Nrf2 inhibition by luteolin (Lut) or 
HO-1 inhibition by ZnPP (Fig. 3A and B). HG exposure significantly increased 
cellular injury manifested as exacerbated MMP loss, increased TUNEL positive cells, 
enhanced cleaved caspase3 protein expression, and elevated LDH release and these 
changes were prevented by gAd. However, the abovementioned cellular protective 
effects of gAd were cancelled by Lut and ZnPP (Fig. 3C-H). gAd significantly 
increased nuclear Nrf2 protein expression but had no impact on cytosolic Nrf2 protein 
expression (Fig. 3I and J) in cardiomyocytes exposed to HG. These were 
accompanied with increased HO-1 protein expression (Fig. 3K) and Brg1 protein 
expression (Fig. 3L). Lut treatment significantly reduced gAd-induced increased 
HO-1 protein expression but had no impact on gAd-induced up-regulation of Brg1 
protein expression (Fig. 3K and L). 
 
Globular Adiponectin Reduced HG-induced Cardiomyocyte Size, Lipid 
Peroxidation, and Cellular Injury via Brg1/Nrf2 Signaling Pathway 
HG significantly increased cultured H9C2 cell size (Fig. 4A and B) and elevated 
cellular 4-HNE expression (Fig. 4C and D), which was associated with increased 
cellular injury manifested as increased TUNEL positive cells and increased LDH 
release (Fig. 4E-G). gAd supplementation prevented these changes. Gene knockdown 
of Nrf2, HO-1, or Brg1 all respectively cancelled gAd cellular protection (Fig. 4A-G). 
gAd supplementation significantly increased nuclear Nrf2, HO-1 as well as Brg1 
protein expression (Fig. 4H-K). Similar to HO-1 gene knockdown, Nrf2 or Brg1 gene 
knockdown attenuated gAd-induced elevation of HO-1 protein expression (Fig. 4J). 
Brg1 gene knockdown had no impact on Nrf2 protein expression both in cytosolic and 
in nuclear fractions (Fig. 4H and I). Similarly, Nrf2 gene knockdown did not affect 
gAd-induced increased Brg1 protein expression (Fig. 4K). HO-1 gene knock down 
cancelled gAd-mediated attenuation of HG-induced cellular injury (i.e., reduction in 
apoptotic cell death and LDH release) without affecting gAd-mediated restoration of 
Brg1 and nuclear Nrf2 protein expression (Fig. 4I and K).   
 
Discussion 
In the current study, we have demonstrated that adiponectin (APN) supplementation, 
through concomitantly activating Nrf2 and Brg1, activates myocardial HO-1 and 
attenuates cardiac hypertrophy and cardiac dysfunction in STZ-induced diabetic rats. 
We showed that in hearts from STZ-induced diabetic rats, reduced myocardial HO-1, 
Brg1, and nuclear Nrf2 protein expression were associated with increased myocardial 
hypertrophy and cardiac dysfunction, which can be partially reversed by APN 
supplementation. We further demonstrated that in isolated adult rat cardiomyocytes as 
well as in H9C2 cells, high glucose (HG) exposure decreased HO-1, Brg1, and 
nuclear Nrf2 protein expression with concomitant increases in lipid peroxidation, 
cardiomyocyte size, and apoptosis. These changes were prevented by globular 
adiponectin (gAd) administration. However, cardioprotective effects of gAd were 
cancelled by Nrf2, Brg1, or HO-1 inhibition/genes knockdown. In addition, Nrf2 or 
Brg1 gene knockdown attenuated gAd-induced HO-1 induction, while Nrf2 gene 
knockdown did not affect Brg1 protein expression, nor did Brg1 gene knockdown 
affect Nrf2, suggesting that HO-1 functions downstream of Brg1 and Nrf2 in 
cardiomyocytes under hyperglycemic condition. . To our best knowledge, this is the 
first study examining the relationship between Nrf2 and Brg1, and their interplay with 
HO-1, in APN mediated cardioprotection against diabetic hypertrophy and cardiac 
dysfunction.  
 
Cardiomyocyte hypertrophy stimulated by enhanced oxidative stress or cell loss 
resulting from apoptosis/necrosis is the main cause of cardiac dysfunction in diabetic 
cardiomyopathy both in humans[28] and animal models of diabetes[4, 29]. In the 
current study, we determined that, in 4-week diabetic rats, APN supplementation 
prevented the increased myocardial oxidative stress (lipid peroxidation and nucleic 
acid oxidation) and enhanced HO-1 and Nrf2 protein expression, and concomitantly 
reduced myocytes apoptosis and the apoptotic activator-cleaved caspase-3 protein 
expression. These abovementioned APN-mediated beneficial effects in attenuating 
diabetic cardiac hypertrophy and apoptosis collectively resulted in improved cardiac 
performance manifested as increased SV, SW, CO, Pes, as well as EF, and augmented 
dP/dtmax and dP/dtmin, with concomitant reductions in Ea and Tau. Our findings were 
similar to the findings of Tao et al who showed that APN attenuated myocardial 
ischemia reperfusion induced cardiac dysfunction and apoptosis by reducing 
oxidative/nitrative stress[30].  
 
Oxidative stress induced by hyperglycemia has been considered as the major cause of 
diabetic cardiomyopathy and that enhancing myocardial antioxidant capacity has been 
proven to be effective in attenuating diabetic cardiomyopathy[1, 2]. Previously studies 
show that APN supplementation ameliorates pressure-induced[15] and angiotensin 
II-stimulated[16] cardiac hypertrophy, which has been assumed to be achieved largely 
through APN mediated metabolic improvement with AMP-dependent protein kinase 
(AMPK) as its main downstream target. However, recent studies show that APN 
reduces post-ischemic myocardial injury mainly through its antioxidative effects 
rather than through metabolic regulation[30]. In addition, exogenous APN 
supplementation could attenuate myocardial apoptosis in cardiomyocytes subjected to 
hypoxic reoxygenation by decreasing NADPH oxidase expression and blocking 
peroxynitrite formation in an AMPK-independent fashion[31]. Similarly, in our 
present study, we provided additional evidences showing that APN exerted 
antihypertrophic and antiapoptotic effects, through its antioxidative properties by 
inducing HO-1 subsequent to its activation of Nrf2 and Brg1.  
 
Nrf2, by regulating a series of cytoprotective genes (i.e. HO-1 and NQO1, NAD(P)H 
dehydrogenase, quinone 1) in response to oxidative stress, is central in myocardial 
cardioprotection against ischemia reperfusion injury[32] and diabetic 
cardiomyopathy[33], especially in the setting of elevated oxidative stress, such as in 
diabetes. However, the role of Nrf2 in APN cardioprotection has not been defined. In 
the current study, Nrf2 inhibition or gene knockdown cancelled APN-mediated 
antihypertrophic and antiapoptotic effects in cardiomyocytes exposed to HG, this 
indicates that Nrf2 played a critical role in APN cardioprotective effects against 
diabetic cardiomyopathy. We further demonstrated that HO-1 inhibition or gene 
knockdown cancelled APN-mediated cardioprotection without affecting APN-induced 
Nrf2 or Brg1 activation (Fig.3 and Fig.4. While Nrf2 inhibition or gene knockdown 
abolished APN-mediated HO-1 induction and compromised APN cardioprotection. 
These suggest that APN conferred its antihypertrophic and antiapoptotic properties 
through Nrf2-mediated up-regulation of HO-1 induction.  
 
The mechanisms whereby Nrf2 mediates HO-1 induction are unclear. In order to 
activate HO-1, activated Nrf2 translocates into the nucleus, binds to AREs, and then 
increases the transcriptional activation of HO-1[34]. This process requires the 
recruitment of Brg1, which facilitates Nrf2 function through chromatin 
remodeling[11]. Consistent with these observations[11, 34], in the present study, gene 
knockdown of Brg1, without affecting Nrf2 expression, abolished APN-induced HO-1 
induction. Zhang et al.[11] reported that Brg1 facilitated Nrf2 to induce HO-1 
induction in response to stress, while Brg1 gene knockdown diminished Nrf2-induced 
HO-1 but had no impact on NQO1, another downstream molecule in Nrf2-mediated 
antioxidative properties[35]. Interestingly, in the current study, Brg1 gene knockdown 
not only abolished Nrf2-mediated APN-induced HO-1 induction but also attenuated 
APN-mediated cardioprotection. These together with the finding in the present study 
that HO-1 inhibition cancelled APN-mediated cardioprotective effect against diabetic 
cardiomyopathy, suggest that activation of Nrf2 contributed to the beneficial effects of 
APN in combating diabetic cardiomyopathy, and that HO-1 served as the main 
downstream target of Nrf2, and this process needed the recruitment of Brg1. 
 
The most novel finding of the present study is that enhancement of Brg1 by APN is 
cardioprotective in diabetic cardiomyopathy. Our findings are in line with the 
observation by Zhang et al.[11] who showed that in response to oxidative stress, Brg1 
facilitated  the recruitment of RNA polymerase II, a critical component in 
Nrf2-mediaeted HO-1 expression, while Brg1 gene knockdown decreased 
Nrf2-mediaeted inducible expression of HO-1 in SW480 cells. It is also reported that 
Brg1 confers cardioprotection by initiating the activation of STAT3[36], a molecule 
mediated propofol-induced cardioprotection against diabetic cardiomyopathy as we 
previous reported[4], and by restoring endothelial nitric oxide synthase (eNOS) 
protein expression and maintaining eNOS transcription in endothelial cells in 
response to hypoxic injury[37]. Further, our present study demonstrated that either 
Brg1 gene knockdown or Nrf2 inhibition/gene knockdown all abolished 
APN-mediated increase in HO-1 expression, suggesting that both Brg1 and Nrf2 were 
required in APN-mediated HO-1 induction in combating myocardial hypertrophy and 
myocardial oxidative stress in diabetes. Of note, in the present study, Nrf2 gene 
knockdown cancelled APN-mediated antioxidative and anti-apoptotic effects (Fig. 
3A-G; Fig. 4C-F) without affecting APN-mediated enhancement of Brg1 expression 
(Fig. 3L and Fig. 4K), which indicates that in the setting of increased oxidative stress 
(where Nrf2 is inactivated), like diabetes, the beneficial effects of Brg1 might be 
diminished or even abolished. 
 
It should be noted that the expression of HO-1 in diabetes seems to be complex since 
several relevant studies have yielded inconsistent results. We[14] have shown that 
HO-1 expression is reduced in STZ-induced diabetes 5 weeks after diabetes induction, 
while others have indicated that HO-1 expression is increased in relative early stage 
(4 weeks) of diabetes while decreased in the relative late stage (8 week) of the 
disease[38]. These indicate that HO-1 expression varies at different stages of diabetes 
(e.g. differences of the severity of the diabetic state and the metabolic profiles after 
diabetic induction). In our current study, HO-1 expression was reduced in vivo in 
diabetic rats but was increased in vitro in isolated cardiomyocytes after HG exposure, 
one possible explanation could be that the cardiomyocyte HG stimulation in our in 
vitro model mimicked the relatively early stage of hyperglycemic induced 
pathological adaptation while our diabetic rat model represents the pathological 
adaptation after prolonged hyperglycemia stimulation. While the consistent findings 
that APN supplementation reduced oxidative stress and cardiomyocyte hypertrophy in 
diabetes by increasing HO-1 induction both in vivo and in vitro indicates HO-1 as a 
critical molecule in APN cardioprotection under diabetic condition. Findings from our 
current study and others suggest that HO-1 may compensatorily increase at the early 
stage of diabetes, while this compensatory in HO-1 is not sufficient to combat diabetic 
cardiomyopathy. As such, induction of endogenous HO-1 production both at the early 
phase and later stage of diabetes represents a major mechanism whereby APN confer 
cardioprotection in diabetes.  
Conclusion 
In summary, to our knowledge, our study demonstrated for the first time, that 
hyperglycemia-induced oxidative stress deactivates Nrf2 and Brg1 which led to the 
reduced HO-1 induction and, consequently, exacerbated myocardial hypertrophy and 
apoptosis (Fig.5). APN supplementation attenuated cardiac hypertrophy and 
dysfunction by concomitantly restoring Nrf2 activation and Brg1 expression and 
subsequently rescuing HO-1 induction, resulting in reduced myocardial oxidative 
stress, decreased cardiac hypertrophy, and reduced cardiac apoptosis, which 
eventually improved cardiac function. Nrf2 and Brg1 activation by APN might 
therefore represent as novel therapeutic targets in the treatment of diabetic 
cardiomyopathy. 
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Figure legends 
Fig. 1. Adiponectin reduced myocardial oxidative stress, cardiomyocyte 
hypertrophy, and apoptosis in 4 weeks streptozotocin-induced diabetic rats. A 
and B, The 4-hydroxynonenal (4-HNE) visualization (400 × magnification, stained in 
brown as indicated by arrow) and quantitation in control (C), diabetic (D) rats, and 
diabetic rats treated with adiponectin adenovirus (D + APN, 1 * 109 pfu) or luciferase 
as control (D + LacZ, 1 * 109 pfu). C, Free 15-F2t-isoprostane (15-F2t-IsoP) in heart 
tissue was measured by suing an enzyme-linked immunoassay kit. D and E, 
Cardiomyocyte nucleic acid oxidation assessed by 8-OHdG staining. 8-OHdG 
positive cells were stained brown as indicated by arrow. F, Myocardial 8-OHdG level 
determined by suing an enzyme-lined immunoassay kit. G and H, Myocardial O2
·- 
production assessed by dihydroethidium (DHE) staining (stained in red) and 
quantification in C, D, D+LacZ, and D+APN. I and J, The cell size visualization (400 
× magnification) and quantitation in C, D, D + LacZ, and D + APN. K and L, The 
collagen I visualization (400 × magnification, stained in brown as indicated by arrow) 
and protein expression in heart tissue. N, Protein expression of cardiac total 
caspases-3 and cleaved caspases-3. M and O, Myocardial cell apoptosis assessed by 
terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). 
TUNEL-positive cells were stained brown as indicated by arrow. Data are shown as 
means ± SEM, with n=8 animals per group. * P<0.05, ** P<0.01. Neg: Negative 
control. 
 
Fig. 2. Adiponectin increased cardiac expression of Brg1, HO-1 and nuclear Nrf2 
in 4 weeks diabetic rats. A and B, cytosolic and nuclear Nrf2 protein expression in 
the myocardium. C, Cardiac HO-1 protein expression. D, Cardiac HO-1 mRNA 
expression. E, Cardiac Brg1 protein expression. Data are shown as means ± SEM, 
with n=8 animals per group. * P<0.05, ** P<0.01. H3: histone H3. 
 
Fig. 3. Globular adiponectin attenuated oxidative stress and apoptosis in isolated 
adult cardiomyocytes exposed to high glucose (HG) for 48hr via Nrf2/HO-1 
signaling pathway. A and B, cellular reactive oxygen species production assessed by 
dihydroethidium (DHE) staining in isolated adult cardiomyocytes exposed to normal 
glucose (NG, 5.5 mM glucose), HG (25 mM glucose), HG + globular adiponectin 
(gAd, 2 μg/mL), HG + gAd + Lut (luteolin, Nrf2 inhibitor), or HG + gAd + ZnPP 
(Zinc protoporphyrin, HO-1 inhibitor). C and D, mitochondrial membrane 
permeability (MMP) loss by JC-1 staining. E and F, cardiomyocyte apoptosis 
assessed by TUNEL staining. G, Protein expression of cardiac total caspase-3 and 
cleaved caspases-3. H, cardiomyocyte death assessed by lactate dehydrogenase (LDH) 
release. I and J, protein expression of cytosolic and nuclear Nrf2. K, protein 
expression of HO-1. L, protein expression of Brg1. Data are mean ± SEM of two 
independent experiments each performed in triplicate, *P<0.05 vs. NG, # P<0.05 vs. 
D + gAd. H3: histone H3. 
 
Fig. 4. Globular adiponectin reduced cardiomyocyte size, lipid peroxidation, and 
cellular injury in H9C2 cardiomyocytes exposed to high glucose (HG) for 48hr 
via Nrf2/Brg1/HO-1 signaling pathway. H9C2 cardiomyocytes were pretreated with 
Nrf2 siRNA, HO-1 siRNA, Brg1 siRNA, or control siRNA and then treated with 
control medium with normal glucose (NG, 5.5 Mm glucose) or HG (25mM glucose) 
for 48hr, subgroup were treated with globular adiponectin (gAd) for 24hr before 
sample collection. A and B, H9C2 cell size visualization (400 × magnification) and 
quantitation. C and D, cellular 4-hydroxynonenal (4-HNE) visualization (400 × 
magnification) and quantitation. E and F, H9C2 cardiomyocyte apoptosis assessed by 
TUNEL staining. G, cardiomyocyte death assessed by lactate dehydrogenase (LDH) 
release. H and I, protein expression of cytosolic and nuclear Nrf2. J, protein 
expression of HO-1. K, protein expression of Brg1. Data are mean ± SEM of two 
independent experiments each performed in triplicate, *P<0.05 vs. NG, # P<0.05 vs. 
D + gAd. H3: histone H3. 
 
Fig. 5. Schematic of proposed signaling involved in APN protects against 
diabetic-induced cardiac hypertrophy and cardiac dysfunction via activation of 
Nrf2 and Brg1. Hyperglycemia-induced oxidative stress by increasing lipid 
peroxidation inactivates Nrf2 by inhibiting its nuclear translocation which associated 
with reduced Brg1, and subsequently reduced HO-1 induction, resulting in 
cardiomyocytes apoptosis and cardiac hypertrophy. APN supplementation activates 
Nrf2 by increasing its nuclear translocation and concomitantly increases Brg1 
expression, which in turn facilities myocardial HO-1 induction, and reduced 
myocardial oxidative stress, improve cardiac function, and attenuates cardiac 
hypertrophy. 4-HNE: 4-hydroxynonenal; 8-OHdG: 8-Hydroxy-2’-deoxyguanosine; 
Keap1: Kelch-like ECII-associated protein 1; ARE: antioxidant response elements. 
Table1. General Characteristics after streptozotocin treatment at termination of study 
 
Parameters C D D + LacZ D + APN 
Water intake (mL/kg/d) 131.60 ± 2.80 753.40 ± 14.10* 780.90 ± 11.60* 449.10 ± 9.40*# 
Food consumption (g/kg/d)  70.30 ± 2.60 179.20 ± 5.90* 180.00 ± 4.20* 136.30 ± 3.10*# 
Body weight (g) 447.50 ± 6.70 298.80 ± 2.80* 296.30 ± 1.60* 317.50 ± 3.70* 
Heart weight (g) 1.50 ± 0.10   0.90 ± 0.10* 1.00 ± 0.10* 1.20 ± 0.10# 
Heart/body weight ratio (g/kg) 3.30 ± 0.10 3.98 ± 0.10*   3.96 ± 0.00* 3.54 ± 0.10*# 
Blood glucose (mM) 6.70 ± 0.20 29.30 ± 1.50* 28.90 ± 1.30* 22.30 ± 0.40*# 
Plasma APN levels (mg/mL) 15.10 ± 2.00 11.30 ± 0.80* 9.80 ± 1.10* 15.20 ± 1.60# 
Heart tissue APN (ng/mg) 270.50 ± 12.00 140.00 ± 14.50** 140.00 ± 8.80** 217.00 ± 8.80*# 
 
 
 
 
 
All values are expressed as mean ± SEM. n=8 per group. Water intake and food consumption were the average value of 
4 weeks. Body weight and plasma glucose were measured at 5 weeks after STZ injection in these five groups. All of the 
indices were measured among groups. *P<0.05, ** P<0.01 vs. C, #P<0.05 vs. D. 
Table 2. Hemodynamic variables and indices of cardiac systolic and diastolic function by pressure-volume conductance catheter system 
 
Parameters C D D+LacZ D+APN 
Heart rate (beats/min) 413.40 ± 3.60 314.90 ± 6.40* 314.90 ± 6.90* 340.70 ± 12.90* 
Stroke volume (μL) 276.50 ± 5.40 155.10 ± 10.20** 165.10 ± 9.40** 261.50 ± 4.60# 
Stroke work (mm Hg/μL) 13,974.00 ± 238.00 9,421.00 ± 706.00* 9,738.00 ± 298.00* 12,778.00 ± 838.00# 
Cardiac output (mL/min) 109.70 ± 3.70 47.33 ± 1.80** 49.00 ± 1.90** 82.70 ± 2.70# 
End-systolic pressure (mm Hg) 114.30 ± 2.80 84.00 ± 2.30* 81.00 ± 4.40* 96.90 ± 1.90# 
End-diastolic pressure (mm Hg)      5.10 ± 0.20 4.80 ± 0.20 4.70 ± 0.30 4.80 ± 0.20 
Ejection fraction (%)     61.00 ± 2.30 46.10 ± 0.70* 45.90 ± 1.00* 61.10 ± 2.00# 
Arterial elastance (mm Hg/μL)      0.56 ± 0.02 0.80 ± 0.02* 0.76 ± 0.02* 0.58 ± 0.03# 
Maximal slope of systolic pressure increment (mm Hg/s) 15,459.00 ± 418.00 6,975.00 ± 207.00** 7,185.00 ± 330.00** 8,518.00 ± 323.00# 
Diastolic decrement (mm Hg/s) 6,609.00 ± 324.00 4,918.00 ± 177.00** 4,938.00 ± 206.00** 5,938.00 ± 227.00# 
Tau (ms) 9.30 ± 0.30 16.9.0 ± 1.30** 16.80 ± 0.70** 8.20 ± 0.30# 
 
 
All values are expressed as mean ± SEM. n=8 per group. All of the indices were measured among groups. *P<0.05, **P<0.01 vs. C, #P<0.05 vs. D. 
